Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology

Journal of the American College of Cardiology

Volumn 32, Issue 6, 1998, Pages 1619-1623

  Ellis, Stephen G ^a   Lincoff, A Michael ^a   Miller, Dave ^a   Tcheng, James E ^b   Kleiman, Neal S ^c   Kereiakes, Dean ^d   Califf, Robert ^b   Topol, Eric J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d CHRIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAPHENOUS VEIN GRAFT; TISSUE DEGENERATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 0032533589     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00403-3     Document Type: Article

References (26)

1. Parisi AF, Folland ED, Hartigan P, and the Veterans Affairs ACME Investigators. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326: 10-6.
2. Mark DB, Nelson CL, Califf RM, et al. Continuing evaluation of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. Circulation 1994;89:2015-25.
3. Detre KM, Holmes DR, Holubkov R, et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-50.
4. Lincoff AM, Popma JJ, Ellis SG, Hacker JA, Topol EJ. Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-35.
5. Kuntz RE, Piana R, Pomerantz RM, et al. Changing incidence and management of abrupt closure following coronary intervention in the new device era. Cathet Cardiovasc Diagn 1992;27:183-90.
6. Scott NA, Weintraub WS, Carlin SF, et al. Recent changes in the management and outcome of acute closure after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993;71:1158-63.
7. Nobuyoshi M, Kimura T, Nosaka H, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12:616-23.
8. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991;84:1426-36.
9. Ellis SG, Roubin GS, King SB, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77: 372-9.
10. Ellis SG, Vandormael MG, Cowley MJ, et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation 1990;82: 1193-1202.
11. Myler RK, Shaw RE, Stertzer SH, et al. Lesion morphology and coronary angioplasty: current experience and analysis. J Am Coll Cardiol 1992;19: 1641-52.
12. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
13. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994;343:881-6.
14. Uchida Y, Hasegawa K, Kawamura K, Shibuya I. Angioscopic observation of the coronary luminal changes induced by percutaneous transluminal coronary angioplasty. Am Heart J 1989;117:769-76.
15. den Heijer P, Foley DP, Escaned J, et al. Angioscopic versus angiographic detection of intimal dissection and intracoronary thrombus. J Am Coll Cardiol 1994;24:649-54.
16. Ellis SG. Coronary lesions at increased risk. Am Heart J 1995;130:643-6.
17. Mak K-H, Challapalli R, Eisenberg MJ, Anderson KM, Califf RM, Topol EJ, for the EPIC Investigators. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. Am J Cardiol 1997;80:985-8.
18. Khan MM, Ellis SG, Aguirre FV, et al. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. J Am Coll Cardiol 1998;31:31-6.
19. Aguirre FV, Topol EJ, Anderson KM, et al. Clinical benefit within patient subgroups receiving c7E3 Fab (abciximab) during percutaneous coronary revascularization: subgroup analysis from the EPIC trial. J Invas Cardiol 1996;8:21B-29B.
20. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
21. Smith SH, Greer JC. Morphology of saphenous vein-coronary artery bypass grafts: Seven to 116 months after surgery. Arch Pathol Lab Med 1983;107: 13-8.
22. Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: observation in animals and humans. Circulation 1997;95:1755-9.
23. Popma JJ, Kennard E, Yeh W, et al. Reproducibility of qualitative and quantitative angiographic findings in the New Approaches to Coronary Intervention (NACI) Registry (abstr.)[special issue]. J Am Coll Cardiol 1995;153A.
24. Kereiakes CJ, Lincoff AM, Simoons ML, et al. Complementarity of stenting and abciximab for percutaneous coronary intervention (abstr.). J Am Coll Cardiol 1997;31 Suppl:54A.
25. Tcheng JE, Lincoff AM, Miller DP, et al. Benefits of abciximab accrue in the full spectrum of coronary interventional patients: insights from the EPILOG trial (abstr.). J Am Coll Cardiol 1997;29 Suppl:276A.
26. Blankenship JC, Hellkamp AS, Demko SL, et al. Vascular access site complications after percutaneous coronary intevention with glycoprotein IIb/IIIa receptor inhibitor therapy in the EPIC trial (abstr.). J Am Coll Cardiol 1997;29 Suppl:278A.